Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.

Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.

Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation

Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist

BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.